Literature DB >> 15908206

Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors.

Scott D Edmondson1, Anthony Mastracchio, Joseph L Duffy, George J Eiermann, Huaibing He, Ida Ita, Barbara Leiting, Joseph F Leone, Kathryn A Lyons, Amanda M Makarewicz, Reshma A Patel, Aleksandr Petrov, Joseph K Wu, Nancy A Thornberry, Ann E Weber.   

Abstract

anti-Substituted biaryl beta-methylphenylalanine derived amides have been shown to be potent DPP-IV inhibitors that suffer from suboptimal selectivity and pharmacokinetics. This letter describes the substitution of the beta-methyl substituent with beta-polar substituents, culminating in the discovery of a beta-dimethylamide substituted phenylalanine derivative with an excellent potency, selectivity, and pharmacokinetic profile.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908206     DOI: 10.1016/j.bmcl.2005.04.028

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  3D-QSAR studies of Dipeptidyl peptidase IV inhibitors using a docking based alignment.

Authors:  Raghuvir R S Pissurlenkar; Mushtaque S Shaikh; Evans C Coutinho
Journal:  J Mol Model       Date:  2007-08-04       Impact factor: 1.810

2.  Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin.

Authors:  Daniel A Tatosian; Ying Guo; Andrea K Schaeffer; Natalia Gaibu; Serghei Popa; Aubrey Stoch; Ronald B Langdon; Eunkyung A Kauh
Journal:  Diabetes Ther       Date:  2013-10-26       Impact factor: 2.945

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.